Jason Kim to Hypoglycemic Agents
This is a "connection" page, showing publications Jason Kim has written about Hypoglycemic Agents.
Connection Strength
0.250
-
Thielen LA, Chen J, Jing G, Moukha-Chafiq O, Xu G, Jo S, Grayson TB, Lu B, Li P, Augelli-Szafran CE, Suto MJ, Kanke M, Sethupathy P, Kim JK, Shalev A. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 09 01; 32(3):353-365.e8.
Score: 0.151
-
Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, Shulman GI. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes. 2003 Jun; 52(6):1311-8.
Score: 0.046
-
Batista TM, Dagdeviren S, Carroll SH, Cai W, Melnik VY, Noh HL, Saengnipanthkul S, Kim JK, Kahn CR, Lee RT. Arrestin domain-containing 3 (Arrdc3) modulates insulin action and glucose metabolism in liver. Proc Natl Acad Sci U S A. 2020 03 24; 117(12):6733-6740.
Score: 0.037
-
Wang H, Knaub LA, Jensen DR, Young Jung D, Hong EG, Ko HJ, Coates AM, Goldberg IJ, de la Houssaye BA, Janssen RC, McCurdy CE, Rahman SM, Soo Choi C, Shulman GI, Kim JK, Friedman JE, Eckel RH. Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes. 2009 Jan; 58(1):116-24.
Score: 0.017